Q-omics provides the consensus-scored PRAMEF9 profile across patient tissues and cancer cell-line models. PRAMEF9 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PRAMEF9 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, PRAMEF9 RNA expression shows 8,030 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, LIHC, and TGCT as cancer lineages where PRAMEF9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF9 survival associations across molecular data types. PRAMEF9 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF9 RNA expression–survival associations across cancer types. High PRAMEF9 expression shows unfavorable associations in BLCA, BRCA, CESC, HNSC, SARC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for PRAMEF9 RNA expression.
This table summarizes PRAMEF9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PRAMEF9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAMEF9 shows higher tumor expression in LIHC. The LIHC box plot shows higher PRAMEF9 RNA expression in tumor versus normal tissue (log2 FC = +0.072, t-test p = .003).
This table shows molecular features associated with PRAMEF9 in patient tissues and cancer cell lines. In patient samples, PRAMEF9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT.
